Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Lonza strikes deal with Israel Biotech Fund

by Michael McCoy
May 26, 2022 | A version of this story appeared in Volume 100, Issue 19

 

Lonza has signed a deal to provide pharmaceutical services to biotech companies in the portfolio of Israel Biotech Fund (IBF), a venture capital firm. Lonza will develop and manufacture both biologics and small molecules. It will also help IBF in its review of potential investment targets. In turn, IBF will provide Lonza with access to Israel’s biotech industry. Lonza has a similar pact with the European venture firms Forbion and BioGeneration Ventures.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.